TY - BOOK AU - Krasnow, Ross E AU - Mohammed, Selma AU - Shaw, Nathan AU - Stamatakis, Lambros TI - Prostate Cancer in Men with Treated Advanced Heart Failure: Should we keep Screening? SN - 0090-4295 PY - 2020/// KW - *Early Detection of Cancer KW - *Heart Failure/co [Complications] KW - *Heart Failure/su [Surgery] KW - *Heart Transplantation KW - *Heart-Assist Devices KW - *Prostatic Neoplasms/co [Complications] KW - *Prostatic Neoplasms/di [Diagnosis] KW - Adolescent KW - Adult KW - Aged KW - Aged, 80 and over KW - Cohort Studies KW - Humans KW - Male KW - Middle Aged KW - Young Adult KW - MedStar Georgetown University Hospital Residents KW - MedStar Heart & Vascular Institute KW - MedStar Washington Hospital Center KW - Urology KW - Journal Article N1 - Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007 N2 - CONCLUSION: Our cohort represents the largest known cohort with heart failure treated by LVAD/HT and PCa. Our median age of 59 at PCa diagnosis is considerably younger than the national median of 66.1 Of the 4 individuals diagnosed with PCa, 3 had high grade disease. Given the favorable long-term survival of these patients post-LVAD/HT, age-appropriate treatment for PCa should be continued post-implantation. Copyright (c) 2019. Published by Elsevier Inc; METHODS: Men aged 18-90 with normal pre-transplant PSA who underwent LVAD/HT at MWHC from 2007-2018 were identified. Serum PSA, PCa diagnosis, and treatment were captured and analyzed. Survival was analyzed using Kaplan-Meier curves; OBJECTIVES: To evaluate the outcomes of men diagnosed with prostate cancer (PCa) following implanted treatments for advanced heart failure. Given the increasingly favorable 10-year life expectancy, MedStar Washington Hospital Center (MWHC) screens heart transplant (HT) candidates for PCa and other malignancies prior to intervention; RESULTS: Data was available for 34 patients. Median age was 53 [IQR=51-58]. Median follow-up was 77mo (95% CI=40-87mo). Six men had post-implant elevated PSA (5.3; SD=8.5) and 4 were diagnosed with PCa. Median age of PCa diagnosis was 59 [IQR=58.5-62). As of 2018, 31 of the 34 patients were living, and none died from PCa. Five-year survival was 96% in those without PCa and 100% in those with PCa (figure 2) UR - https://dx.doi.org/10.1016/j.urology.2019.11.022 ER -